MedTrace Logo

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 620

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Conditions

Interventions

DRUG

Placebo

ARM 1

DRUG

Low Dose PF-07328948

ARM 2

DRUG

Medium Dose PF-07328948

ARM 3

DRUG

High Dose PF-07328948

ARM 4

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-19
Primary Completion
2027-11-16
Completion
2027-12-14
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Bulgaria
  • Canada
  • China
  • Czechia
  • France
  • Hungary
  • Japan
  • Poland
  • Puerto Rico
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06991257 on ClinicalTrials.gov